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To investigate the role of different regions of hirudin in the interaction with the proteinase thrombin, segments of hirudin containing 15-51 residues 
were synthesized. The C-terminal segment 4&65 inhibited the fibrinogen clotting activity of thrombin but not amidolysis of tosyl-Gly-Pro-Arg-p- 
nitroanilide. Central peptide 1+%2 was insoluble at pH 7, but peptide 15-65 inhibited fibrinogen clotting and amidolysis to an equal extent. The 
N-terminal loop peptide 1-15 had no inhibitory activity and did not affect the potency of peptide 1545. These data suggest hat the central region 
inhibits catalysis. 
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1. INTRODUCTION 
Hirudin, a potent anticoagulant from the leech 
Hirudo medicinalis [1,2] is a 65residue protein that 
specifically inhibits the enzyme thrombin [3]. The bin- 
ding of hirudin to thrombin is extremely tight, with an 
inhibition constant, Ki, of 8 x lo- l1 - 2 x lo- l4 M 
[4-61, and hirudin can be displaced from thrombin with 
a high concentration of competing substrate [5,6]. Syn- 
thetic hirudin peptide 45-65 inhibits fibrinogen 
cleavage but not amidolysis of small peptide substrates 
by thrombin [7], so the region of hirudin that blocks the 
catalytic site of thrombin is not the C-terminus. The 
aim of this study was to investigate the role of specific 
regions of hirudin in the interaction with thrombin us- 
ing synthetic peptide segments 15-51 amino acid 
residues in length. Two thrombin assays were used to 
investigate the inhibitory effects of these peptides, a 
fibrinogen clotting assay and a tripeptide amidolytic 
assay [7]. 
the resin the 2,4_dinitrophenyl group on histidine was removed with 
2-mercaptoethanol/diisopropylethylamine/dimethyl formamide 
(2: 1:7, v/v) for three 30-min periods [9]. Peptides were cleaved from 
the resin by treatment with liquid hydrogen fluoride. 
2.3. Peptide purification and folding 
Peptides lacking cysteine were purified by reverse-phase HPLC. 
Each peptide containing cysteine was converted into the S-sulfonate 
derivative [lo], the sulfonated peptide was purified by HPLC, the 
sulfonate groups were removed by reduction, and the free peptide was 
folded by air oxidation in dilute solution. 
2.4. Peptide analysis 
Analytical scale HPLC was performed on an Aquapore RP-300 C8 
column (30 x 2.1 mm) using linear gradients of acetonitrile in 0.1% 
trifluoroacetic acid. Preparative HPLC was performed on an 
Aquapore OCTYL C8 column (10 x 1 cm). Amino acid compositions 
were determined after hydrolysis in 6 N HCI at 110°C for 24 h. Pep- 
tides were sequenced using an Applied Biosystems Model 470A se- 
quencer. Polyacrylamide gel electrophoresis was performed in the 
presence of urea [ 111. The disulfide-bridged peptides were tested for 
the presence of free sulfhydryl groups with dithiobis(2-nitrobenzoic 
acid) as a quantitative calorimetric reagent [ 121. 
2.5. Clotting assay 
2. EXPERIMENTAL 
2.1. Marerials 
Reagents for peptide synthesis were supplied by Applied 
Biosystems Inc. Trypsin-agarose, thermolysin and SDS molecular 
weight markers were supplied by Sigma Chemical Co. Human w 
thrombin was a gift from John Fenton III. Tosyl-Gly-Pro-Arg-p- 
nitroanilide (Chromozym TH) was supplied by Boehringer Mann- 
heim. Human fibrinogen (96% clottable) was from Kabi Diagnostica. 
2.2. Peptide synthesis and cleavage 
All peptides were assembled by automated solid-phase synthesis us- 
ing tert-butyloxycarbonyl (Boc) protection. Prior to cleavage from 
Correspondence and present address: C.G. Binnie, Department of 
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Competition for the secondary fibrinogen-binding site on thrombin 
was measured by a turbidimetric clotting assay. Solutions contained 
0.05 M Tris at pH 7.8, 0.1 M NaCl, 0.1% PEG 6000 and 5 pM 
fibrinogen. The concentration of Aor chains was 10 CM, which is close 
to the K,,, determined for human Aol cleavage by human thrombin 
[13,14]. Peptide concentration was verified by quantitative amino 
acid analysis. Fibrin formation was followed by optical turbidity at 
350 nm for 60 min. The concentration of non-inhibited thrombin was 
determined by comparison to a set of curves obtained by using the 
same assay with a series of lower thrombin concentrations in the 
absence of inhibitor. The inhibition constant was calculated as Ki = 
[free thrombin][peptide]/[complexed thrombin], where [peptide] was 
the free peptide concentration (not significantly different from the 
total peptide concentrations under the used conditions), [free throm- 
bin] was taken as one half the concentration of non-inhibited throm- 
bin, calculated from the residual thrombin activity (non-inhibited 
thrombin being divided equally between free enzyme and fibrinogen- 
bound enzyme when the substrate concentration equals K,), and 
[complexed thrombin] equals the difference between total and non- 
inhibited thrombin concentrations. 
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Hirudin WYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIPEEYLQ 
I I J 
Segment 1-15 WYTDCTESGQNLCL 
Segment 15-42 LCEGSNVCGQGNKCILGSDGEKNQCVTG 
Segment 15-65 LCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIPEEYLQ 
Segment 29-65 (A39) ILGSDGEKNQBVTGEGTPKPQSHNDGDFEEIPEEYLQ 
Segment 40-65 VTGEGTPKPQSHNDGDFEEIPEEYLQ 
Fig. 1. Diagram of the primary sequence of hirudin and the synthetic segments ynthesized in this report. Amino acids are listed according to 
their standard one-letter code. A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; N, Asn; P, Pro; Q, Gin; S, Ser; 
T, Thr; V, Val; Y, Tyr. The location of the 3 disulfide bridges is indicated. Native hirudin is sulfated at Tyr-63. 
2.6. Amidolytic assay 
Amidolysis of the tripeptide toxyl-Gly-Pro-Arg-p-nitroanilide 
(Chromozym TH) was measured by release of p-nitroaniline at 405 
nm [IS]. In peptide-inhibited samples, peptide was mixed with throm- 
bin prior to the addition of the chromogenic substrate. The K, and 
Ki values were determined from a Lineweaver-Burk plot. For each 
peptide the experiment was repeated at 3 different concentrations to 
establish the measured Ki was concentration-independent a d ensure 
that the inhibition was simply competitive. 
2.7. Cleavage by agarose-immobilized trypsin and thrombin 
Lyophilized peptide (1 .O mg) was dissolved in 400 pl of clotting buf- 
fer. Approximately 120 ~1 (6 BAEE units) of trypsin-agarose or 
thrombin was added and the slurry was mixed overnight at room 
temperature. The supernatant was subjected to analytical HPLC. 
3. RESULTS 
3.1. Peptide 40-65 
Sequences of 5 synthetic peptides are shown in Fig. 1. 
There inhibition constants for fibrinogen cleavage and 
tripeptide amidolysis are given in Table I and amino 
acid compositions are given in Table II. Peptide 40-65, 
the negatively charged 26-residue C-terminal segment 
of hirudin inhibited clotting of fibrinogen by thrombin 
with a Ki of 3.0 x lo- 6 M (Fig. 2). Peptide 40-65 had 
no inhibitory effect on cleavage of the tripeptide anilide 
even at a peptide concentration of 0.2 mM, which was 
50 times higher than that showing effect in the 
fibrinogen cleavage assay. The inhibition constant was 
too high to measure but it cannot be lower than 5 x 
10m4 M. The lack of activity in the amidolytic assay in- 
dicated that peptide 40-65 does not contain a sequence 
capable of blocking the catalytic site of thrombin. Pep- 
tide 40-65 contains a single lysine, Lys-47, and incuba- 
tion with trypsin resulted in cleavage of peptide 40-65 at 
this position. Thrombin did not cleave the peptide. 
Either the sequence was not recognized as a site of 
cleavage by thrombin or a lysine-proline bond cannot 
be cleaved by thrombin, since a lysine-proline scission 
has yet to be described for thrombin [ 16,171. 
3.2. Peptide 29-65(A39) 
The hirudin segment 29-65 contains a single cysteine 
residue at position 39, that could interfere with the ac- 
tivity assays or lead to peptide dimerization, so peptide 
29-65 was synthesized with an alanine residue in place 
Peptide 
40-65 
29-65(A39) 
15-65 
15-42 
1-15 
Table I 
Inhibition of thrombin-catalyzed amidolysis and fibrinogen clotting by synthetic hirudin peptides 
Amidolysis Clotting Potency ratiob 
Ki (M) Rel. Potency (To)~ Ki (M) Rel. Potency (o/o)” 
>5 x 10-4 < 0.03 3.0 x 10-6 3 <O.Ol 
3.0 x 10-s 0.4 1.1 x 10-6 8 0.05 
1.3 x 10-7 11~1 0.9 x lo-’ 11001 111 
insoluble insoluble 
>5 x 10-4 co.03 >5 x 1o-4 <0.02 
Synthetic peptides were incubated with human thrombin either in the presence of 2.3-50 mM of tosyl-Gly-Pro-Arg-p-nitroanilide for measuring 
amidolysis or 4 PM fibrinogen for measuring fibrinogen clotting inhibition. 
‘Relative to 15-65. 
‘Potency ratio = relative amidolysis potency/relative clotting potency. 
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Table II 
Peptide 
Amino acid analysis of synthetic hirudin segments 
40-65 29-65(A39) 15-42 l-15 15-65 
Asx 2.34 (3) 1.51 (7) 4.19 (4) 1.90 (2) 7.51 (7) 
Glx 5.69 (7) 10.85 (11) 4.18 (4) 2.17 (2) 10.85 (11) 
Ser” 0.70 (1) 2.23 (3) 1.55 (2) 0.95 (1) 2.23 (3) 
GlY 2.30 (3) 6.93 (8) 5.95 (6) 1.25 (2) 1.93 (8) 
His 0.73 (1) 1.07 (1) 1.07 (1) 
Thr 1.93 (2) 2.23 (2) 0.99 (1) 2.00 (2) 2.23 (2) 
Pro 3.17 (3) 3.92 (3) 3.92 (3) 
Tyr 1.04 (1) 1.35 (1) 1.00 (1) 1.35 (1) 
Val 1.09 (1) 1.64 (2) 1.85 (2) 1.69 (2) 1.64 (2) 
Ile 1.16 (1) 2.17 (2) 1.97 (2) 2.17 (2) 
Leu 1 .OO (1) 2.74 (3) 2.27 (2) 2.74 (3) 
Phe 1.08 (1) 1.45 (1) 1.96 (2) 1.45 (1) 
LYS 1.46 (1) 2.15 (3) 2.15 (3) 
Ala 1.00 (1) 
CYS n.d. (4) n.d. (4) n.d. (2) n.d. (4) 
Peptides were hydrolyzed in 6 M HCl for 24 h at 110°C. The amino acids were converted into the PTH derivatives and analyzed by reverse-phase 
HPLC. The theoretical number is listed in parentheses. n.d., not determined. 
‘Not corrected for decomposition during hydrolysis. 
of Cys-39. The expected sequence was confirmed by 
Edman sequencing. Peptide 29-65(A39) inhibited 
fibrinogen clotting with a Ki of 1.1 x lob6 M, which is 
slightly lower than for peptide 40-65. At a concentra- 
tion giving marked inhibition in the fibrinogen clotting 
assay, a small but detectable effect was seen in the 
amidolytic assay, so it was necessary to increase the 
peptide concentration lo-fold to quantitate this effect. 
Fig. 3 shows the effect of peptide 29-65(A39) on tripep- 
tide amidolysis. The decrease in cleavage was consistent 
with competitive inhibition with a Ki of 3.0 x lo-’ M. 
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Fig. 2. Inhibition of fibrinogen clotting by hirudin peptide 40-65. 
Fibrinogen (5 CM, in 0.1 M NaCl, 50 mM Tris, pH 7.8, 0.1% PEG) 
was clotted by addition of l-5 pl of a stock solution of thrombin ( q : 
curves l-5, final thrombin cont. = 0.023-0.115 nM) and the rate of 
cleavage was measured by the formation of fibrin gel as revealed by 
turbidity at 350 nm. The inhibition constant of peptide 40-65 was 
measured by clotting (0.115 nM thrombin) in the presence of peptide 
(m. 9 x lo-’ M; A, 1.8 x 1O-6 M). 
This peptide was not cleaved by incubation with 
thrombin. 
3.3. Peptide IS-65 
Peptide 15-65 contained no free sulfhydryl groups 
(C 0.1 mol/mol peptide), indicating that the cysteines 
had been oxidized to form disulfide bonds. On 
polyacrylamide gel electrophoresis, peptide 15-65 pro- 
duced a main band with an apparent molecular weight 
of 7000 Da. The molecular weight expected from the se- 
quence was 5500 Da, so this band is consistent with a 
folded monomer. A band of higher molecular weight 
containing 5-10070 of the stain was evident and pro- 
bably represents asmall amount of peptide dimer which 
formed during folding. The first 30 residues were 
verified by direct Edman sequencing. Digestion with 
thermolysin (2 mol%) for 24 h produced several major 
fragments, which were sequenced and found to be pep- 
tide fragments 40-48, 53-63 and 58-63 from the C- 
terminal region. Such a digestion pattern would be ex- 
pected if an exposed C-terminus (residues 40-65) were 
connected to a central region (residues 15-39) cross- 
linked by two disulfide bonds. Peptide 15-65 inhibited 
both fibrinogen clotting (Ki = 0.9 x lo-’ M) and 
tripeptide amidolysis (Ki = 1.3 x 10 - ’ M) with nearly 
equal potency. Variants of peptide 15-65 with lysines at 
position 27 or 36 substituted by alanine were synthesiz- 
ed. The inhibition constants for both thrombin assays 
did not differ significantly from those of 15-65: Ki for 
amidolysis and clotting for the Ala-27 variant was 2.2 
x lo-’ M and 2.1 x lo-’ M; for the Ala-36 variant 
was2.5 x lo-‘M and 3.1 x lo-‘M. 
3.4. Peptide 15-42 
Peptide 15-42, containing the central region of 
hirudin, did not dissolve in neutral or basic buffer. It 
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Fig. 3. Competitive inhibition of thrombin amidolytic activity by 
hirudin 29-G(A39). Lineweaver-Burk plot shows the effect of 
hirudin on the amidolytic activity of human thrombin. The enzyme 
activity was measured by cleavage of the chromogenic substrate 
Chromozym TH (tosyl-Gly-Pro-Arg-p-nitroanilide). The release ofp- 
nitroaniline was followed by absorbance at 405 nm. Control, 0; 
Inhibited with 2 x lo-’ M peptide, +. The apparent Ki determined 
from these data was 3.0 x 10-s M. 
dissolved completely in highly acidic solutions but 
precipitated when neutralized by adding dilute am- 
monia. Since the purified peptide was insoluble at the 
basic pH used for disulfide formation it was not possi- 
ble to test its inhibitory effect. 
3.5. Peptide I-15 
Hirudin peptide l-15, which contains the N-terminal 
disulfide loop, had no antithrombin activity in either 
assay. At peptide concentrations of 1.2-30 mM there 
was no detectable inhibition of fibrinogen cleavage in 
the fibrinogen clotting assay and no significant inhibi- 
tion of amidolysis. A mixture of both fragments 1-15 
and 15-65 at a concentration of 1 mg/ml in assay buffer 
(approximately a 3: 1 molar ratio) was tested for activity 
in both assays. The degree of inhibition corresponded 
to that produced by peptide 15-65 alone. Despite a 
3-fold excess of peptide I-15, this hirudin segment had 
no apparent effect in the binding of the remainder of 
the molecule. 
4. DISCUSSION 
Hirudin interacts with thrombin at the substrate- 
binding site and the catalytic site. Binding to the 
substrate-binding site is demonstrated by the ability of 
hirudin C-terminal peptides to inhibit fibrinogen clot- 
ting [7,18-201. Binding to the catalytic site is 
demonstrated by a 106-fold decrease in affinity for 
hirudin on modification of the catalytic histidine in 
thrombin [21]. Results from this study indicate that the 
region of hirudin responsible for blocking the catalytic 
site of thrombin is present in residues 15-39. 
Amidolysis inhibition appeared when the C-terminal 
peptide 40-65 was extended by 25 residues to include 
the central core to give 15-65. Peptide 40-65 did not in- 
hibit amidolysis even at high concentrations but peptide 
15-65 had considerable activity. Intermediate peptide 
29-65(A39) showed weak inhibition of amidolysis since 
20-fold higher concentrations of peptide were needed to 
inhibit amidolysis than were required to inhibit 
fibrinogen clotting. 
These results for peptide 40-65 are similar to those 
for peptide 45-65 [7], namely, inhibition of fibrinogen 
clotting but no effect on the amidolytic activity of 
thrombin. The increase in relative potency on going 
from peptide 29-65 to peptide 15-65 was 1Zfold for 
clotting but 250-fold for amidolysis, suggesting that 
15-65 blocks the catalytic site of thrombin. The dif- 
ference in Ki between amidolysis and clotting for pep- 
tide 29-65(A39) is most easily explained by flexibility of 
the bound peptide: bound peptide always occupies the 
fibrinogen binding site, but this peptide lacks the 
necessary residues to completely block the catalytic site. 
Incomplete shielding is reflected in the numerically 
larger inhibition constant for amidolysis. 
The difference between peptides 15-65 and 40-65 is 
the presence of residues 15-39. The appearance of in- 
hibition against amidolysis when these residues are pre- 
sent indicates that residues in this region block the 
thrombin catalytic site, however, peptide 15-65 was on- 
ly l/200 as potent as desulfato-hirudin (Ki = 5 x lo- lo 
M) [22]. HPLC indicated that peptide 15-65 contained 
more than one species but insufficient material was 
available to determine what fraction was most active 
and the inhibition constants reported are averages for 
the mixture, the most conservative case. 
N-terminus and central core fragments of recombi- 
nant hirudin have been shown to be potent inhibitors of 
thrombin [23-251. The hirudin fragment l-52 has a Ki 
of 2.4 x 10e8 M [23], fragment l-47 has a Ki of 6.0 X 
10m7 M [24], and fragment l-43 has a& of 3.0 x 10m7 
M [25]. The resulting protection of thrombin from 
elastase digestion and inhibition of amidolytic activity 
is consistent with binding near the catalytic site of 
thrombin. 
Replacing two of the 3 lysines in peptide 15-65, 
Lys-27 and Lys-36, separately by alanine had no signifi- 
cant effect on the inhibition of fragment 15-65. Two 
studies in which each of the 3 lysines in recombinant 
hirudin were separately substituted by non-basic 
residues also reported a minimal effect [26,27], sug- 
gesting that lysine residues are not essential for hirudin 
to act as a potent inhibitor. Neither peptide 40-65, 
which contained a single lysine residue, nor peptide 
29-65(A39), which contained two lysine residues, were 
cleaved by overnight treatment with thrombin. 
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Acetylation or substitution of the two N-terminal 
valine residues of hirudin with polar amino acids results 
in markedly decreased affinity for thrombin [28], in- 
dicating the importance of this region in the interaction 
with thrombin. Peptide 1-15 did not inhibit either 
fibrinogen clotting or amidolysis. Incubation of throm- 
bin with peptide 15-65 in the presence of peptide 1-15 
resulted in a degree of inhibition equivalent o that of 
peptide 15-65 alone. This suggests that covalent attach- 
ment of 1-15 to the rest of the molecule is essential to 
fulfil its function. For comparison, hirudin fragment 
l-52 exhibits a modest, 2-fold cooperativity in the 
presence of the complementary fragment 53-65 [23]. 
Peptide 15-42, the isolated central core of hirudin, 
was insoluble in neutral aqueous buffer. The results 
reported here indicate that the central core of hirudin, 
residues 15-39, when solubilized by attachment o the 
C-terminal part of the molecule, blocks the catalytic site 
of thrombin. Both results by others [23-251, using 
fragments of recombinant hirudin and the ones we 
report in this paper for synthetic fragments, support the 
binding of the central core of hirudin to the catalytic 
site of thrombin. 
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